Altimmune with ticker code (ALT) now have 8 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 50 and 20 with the average target price sitting at 29.13. With the stocks previous close at 11.85 this now indicates there is a potential upside of 145.8%. There is a 50 day moving average of 13.8 and the 200 day moving average is 12.1. The company has a market capitalisation of $589m. Find out more information at: https://altimmune.com
The potential market cap would be $1,448m based on the market concensus.
Altimmune, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune in September 2015. Altimmune was founded in 1997 is headquartered in Gaithersburg, Maryland.
